It has been shown that ERK activation can mediate NSCLC cell death in response to c‐Met inhibitors,44 and MEK inhibitors have been shown to be effective against MET‐amplified NSCLC cells.45 Here, MAP2K7 is linked to non-small cell lung carcinoma.